此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

2020年10月7日 更新者:University of North Carolina, Chapel Hill

19F Magnetic Resonance Imaging of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

The purpose of this study is to use perfluorinated gas imaging to highlight regions of functional variation within the lungs of participants with cystic fibrosis (CF), and to correlate this with changes in spirometry, lung clearance index, and quality of life of CF subjects undergoing treatment for a pulmonary exacerbation.

研究概览

详细说明

The investigators hypothesize that 19F-enhanced MRI will detect improvements in lung ventilation following the treatment of a CF pulmonary exacerbation, and changes in ventilation as well as global MRI scores will track with both spirometry and quality of life assessments. Therefore, investigators propose this pilot and feasibility study to gain preliminary data on a comparison of the changes in ventilation that occur with treatment of a pulmonary exacerbation, as well as to begin to understand the repeatability of this novel outcome measure. Through this study, the investigators aim to: 1) Compare quantitative and qualitative assessments of lung ventilation using 19F MRI imaging and traditional, global physiologic assessments (spirometry, LCI) and compare these with images obtained in an age-matched healthy control population; 2) Correlate changes in MRI scoring with subjective changes in health related outcomes as measured by the CFQ-R (Cystic Fibrosis Questionnaire - Revised); 3) Determine the ability of 19F MRI to detect changes in ventilation that occur with treatment of a CF pulmonary exacerbation; and 4) Determine the repeatability of 19F MRI assessment of ventilation in a disease population.

Participants with CF with baseline forced expiratory volume in 1 second (FEV1) of at least 40%, no contraindications to MRI, and oxygen saturation >90% on room air will be prospectively enrolled. Investigators will recruit a pre-defined cross-section of CF patients with mild, moderate, and severe lung disease, with approximately 4 subjects per group at the onset of a disease exacerbation requiring antibiotic intervention. The research team will obtain a pre-response MRI (within 3 days of initiating oral, inhaled, or IV antibiotic therapy), and a post-treatment MRI (within 3 days of terminating antibiotic treatment) to assess the responsiveness of 19F-MRI to a change in disease status. Each 19F-MRI study will be combined with assessments of spirometry, LCI (multiple breath nitrogen washout), and quality of life (CFQ-R quality of life tool).

19F-MRI will be performed by having each participant inhale a mixture of 79% perfluorinated propane (PFP) and 21% oxygen (pre-mixed) while using MRI to obtain 3D images. Subsequently, participants will be switched to room air, and cycled breathing will be continued while additional MRI images are captured to characterize gas wash-out. Safety measures, including pulse oximetry, will be monitored continuously, and spirometry will be performed before and after each MRI. Participants will also perform multiple breath washout maneuvers to obtain a lung clearance index, so this may be correlated to wash-out kinetics of the PFP.

研究类型

介入性

注册 (实际的)

5

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • University of North Carolina at Chapel Hill

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 99年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Non-smokers (<10 pack year history and no active smoking in the past year);
  • Diagnosis of cystic fibrosis via standard sweat chloride/phenotypic features/genotyping
  • Able to reproducibly perform lung function testing and have an FEV1 >30% of predicted at screening.
  • No requirement for supplemental oxygen
  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
  • Participants must be willing and able to comply with scheduled visits and other trial procedures.
  • Diagnosis of a pulmonary exacerbation according to Fuchs criteria (4 of the following 12 signs and symptoms) deemed to require antibiotic treatment, and must also include the change in lung function criterion:

    • Change in sputum
    • New or increased hemoptysis
    • Increased cough
    • Increased dyspnea
    • Malaise, fatigue, or lethargy
    • Temperature above 38deg C
    • Anorexia or weight loss
    • Sinus pain or tenderness
    • Change in sinus discharge
    • Change in physical examination of the chest
    • Decrease in pulmonary function by 10% or more from a previously recorded value
    • Radiographic change indicative of pulmonary infection

Exclusion Criteria:

  • Under 18 years of age
  • Active or former smokers with less than 1 years since quitting, or >10 pack-year smoking history
  • Active asthma flare, as perceived by the study physician or unstable asthma characterized by advancement of asthma therapy in the last month or two courses of oral steroids in the past six months.
  • Unable to undergo a 3.0-Tesla MRI of lungs and chest because of contraindications including

    1. Occupation (past or present) of machinist, welder, grinder
    2. Injury to the eye involving a metallic object
    3. Injury to the body by a metallic object (bullet, BB, shrapnel)
    4. Presence of a cardiac pacemaker or defibrillator
    5. Presence of aneurysm clips
    6. Presence of carotid artery vascular clamp
    7. Presence of neurostimulator
    8. Presence of insulin or infusion pump
    9. Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of University of North Carolina Hospitals (UNCH) or is older than 10 years)
    10. Bone growth or fusion simulator
    11. Presence of cochlear, otologic or ear implant
    12. Any type of prosthesis (eye, penile, etc.)
    13. Artificial limb or joint
    14. Non-removable electrodes (on body, head or brain)
    15. Intravascular stents, filters or coils
    16. Shunt (spinal or intraventricular)
    17. Swan-Ganz catheter
    18. Any implant held in place by a magnet
    19. Transdermal delivery system (e.g. Nitro)
    20. Intrauterine device (IUD) or diaphragm
    21. Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area
    22. Body piercings (MUST BE REMOVED BEFORE MRI)
    23. Any metal fragments
    24. Internal pacing wires
    25. Metal or wire mesh implants
    26. Hearing aid (REMOVE BEFORE MRI) aa. Dentures (REMOVE BEFORE MRI) bb. Claustrophobia
  • Unable to tolerate inhalation of the gas mixture
  • Unable to adequately complete other study measures, including spirometry and multiple breath nitrogen washout
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the PI, would make the participant inappropriate for enrollment.
  • Pregnancy; women of childbearing potential must have a confirmed negative serum pregnancy test at screening, and a negative urine test on the day of the MRI scan, prior to the MRI scan (if serum test not performed the same day).
  • Facial hair preventing a tight fit of the mask used in the study
  • Allergy or intolerance due to side effects to bronchodilators

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:CF pulmonary exacerbation group

Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.

LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.

PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.

To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
其他名称:
  • 生命周期指数
  • Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)
  • Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.
  • Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.
  • Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
其他名称:
  • 全氟丙烷气体 (C3F8); 19F

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Whole lung ventilation defect volume (VDV)
大体时间:1 day
To obtain ventilation defect volumes (VDVs), investigators will use the final wash-in image to identify all regions of interest having a signal intensity below the pre-defined threshold which indicates poor ventilation. The combined volume of all these 'ventilation defect' regions will be computed to obtain the VDV.
1 day

次要结果测量

结果测量
措施说明
大体时间
The wash-in kinetics of PFP
大体时间:1 day
For each participant, an exponential model will be fit to obtain a statistical estimate, T, of the rate constant that characterizes the kinetics of gas wash-in. Aggregating across all participants, the frequency distributions of T values will be characterized by tabulating estimates of the mean and standard deviation (SD). Corresponding 95% confidence intervals and the minimum, maximum, and interquartile range of T values will also be tabulated.
1 day
Ventilation defect percent (VDP) correlation with LCI
大体时间:1 day
Changes in VDP from pre/post treatment will be correlated with changes in LCI pre- and post-exacerbation.
1 day
Ventilation defect percent (VDP) correlation with FEV1
大体时间:1 day
Changes in VDP from pre/post treatment will be correlated with changes in FEV1 pre- and post- exacerbation.
1 day

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jennifer Goralski, MD、University of North Carolina, Chapel Hill

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年8月25日

初级完成 (实际的)

2019年9月13日

研究完成 (实际的)

2019年9月13日

研究注册日期

首次提交

2018年3月29日

首先提交符合 QC 标准的

2018年4月5日

首次发布 (实际的)

2018年4月13日

研究记录更新

最后更新发布 (实际的)

2020年10月9日

上次提交的符合 QC 标准的更新

2020年10月7日

最后验证

2020年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Lung Clearance Index的临床试验

订阅